USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Global Pharmaceutical Industry Growth Opportunities
Global Pharmaceutical Industry Growth Opportunities
2021 Highlights and What to Expect in 2022
02-Dec-2021
North America
Description
The global pharmaceutical industry is witnessing dynamic trends following the coronavirus pandemic and is adapting to new challenges and opportunities. This study analyzes the 2021 highlights in the global pharmaceutical industry and provides forecasts for the next year and beyond.
It addresses the impact of innovative modalities, technologies, and recent drug approvals, such as gene and cell therapy, monoclonal antibodies,
RNA-based therapeutics, and the increasing use of health data through real-world evidence and artificial intelligence. The need to gain access to early-stage drugs and novel technologies has led to a higher rate of licensing and mergers with small biopharma that are developing the same. In addition, patient engagement has been driving digital partnerships centered around digital therapeutics, decentralized clinical trials, remote monitoring, and telemedicine.
The study also provides critical insights into the key regulatory, reimbursement, and policy updates for 2021, ranging from health data standardization and quality regulation to direct drug pricing negotiations and biosimilars & generics encouragement.
Table of Contents
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Strategic Imperative 8™ on the Pharmaceuticals Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Pharmaceuticals—Factors Affecting Growth
Growth Opportunity Analysis for the Global Pharmaceutical Industry
2021 Highlights and What to Expect in 2022
2021 Highlights and What to Expect in 2022 (continued)
2021 Highlights and What to Expect in 2022 (continued)
Growth Drivers
Growth Restraints
Market Snapshot—Next-generation Biologics Modalities
Key FDA Approvals for Novel Drugs
Key FDA Approvals for Novel Drugs (continued)
Key FDA Approvals for Novel Drugs (continued)
Key FDA Approvals for Novel Drugs (continued)
Key FDA Approvals for Novel Drugs—Takeaways
Key M&A Deals
Key M&A Deals in the Pharma Industry—Takeaways
Key Product Licensing Deals
Key Product Licensing Deals (continued)
Key Product Licensing Deals (continued)
Key Product Licensing Deals—Takeaways
Key Digital Partnership Deals
Key Digital Partnership Deals (continued)
Key Digital Partnership Deals—Key Takeaways
Key Digital Partnership Deals—Key Takeaways (continued)
Key Regulatory, Reimbursement, and Policy Updates
Key Regulatory, Reimbursement, and Policy Updates (continued)
Key Regulatory, Reimbursement, and Policy Updates (continued)
Key Regulatory, Reimbursement, and Policy Updates (continued)
Key Regulatory, Reimbursement, and Policy Updates (continued)
Key Regulatory, Reimbursement, and Policy Updates (continued)
Key Regulatory, Reimbursement, and Policy Updates—Takeaways
Growth Opportunity 1: Novel Drug Modalities and RNA Therapeutics Transforming R&D Productivity
Growth Opportunity 1: Novel Drug Modalities and RNA Therapeutics Transforming R&D Productivity (continued)
Growth Opportunity 2: Integrated and RWE-supported Drug Development Platforms/Solutions to Improve User Experience
Growth Opportunity 2: Integrated and RWE-supported Drug Development Platforms/Solutions to Improve User Experience (continued)
List of Exhibits
Legal Disclaimer
Related Research
Popular Topics
Key Issue Addressed
- What should we expect in the global pharmaceutical industry in 2022
| No Index | No |
|---|---|
| Podcast | No |
| Author | Delfina Huergo |
| Industries | Healthcare |
| WIP Number | MG4D-01-00-00-00 |
| Is Prebook | No |
| GPS Codes | 9600-B1,9571-B1,9568-B1,9611-B1 |